Please select the option that best describes you:
Would you consider stopping maintenance immunotherapy for ES-SCLC after 2 years for exceptionally responding patients?
Would you differentiate between patients with measurable disease vs NED? Are there specific data to guide us?
Answer from: Medical Oncologist at Academic Institution
If therapy is well tolerated, I support indefinite use. While it is rare to see late recurrence in NSCLC after 2 years, I have seen late recurrence regularly in SCLC.
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
I know of no data to guide stopping points for patients with extensive stage SCLC who have had exceptional responses to chemo-immunotherapy. My practice is to check a PET/CT and if no evidence of disease I would have the discussion of stopping the maintenance immunotherapy with the patient.&nb...